This application continues the investigation of short chain fatty acid-N-acetylmannosamine (SCFA-ManNAc) analogs represented by the lead compound Bu4ManNAc. This hybrid molecule derives HDACi growth inhibitory activity from its n-butyrate (Bu) groups and increases metabolic flux through the sialic acid biosynthetic pathway due to ManNAc generated after complete removal of n-butyrate by esterases. During the initial funding period of this project, it was discovered that partial hydrolysis products of Bu4ManNAc (e.g., 3,4,6-O-Bu3ManNAc) have a third mode of activity that suppresses the invasive potential of metastatic breast cancer cells at subcytotoxic doses. Because of the largely unmet and urgent clinical need for anti-metastatic therapeutics, the second funding period will investigate the mechanism underlying this newly found anti-cancer activity by focusing on the ability of the analogs to inhibit NF-kB (Aim 1) and alter glycosylation (Aim 2);in tandem, the current emphasis on cell-based assays will be transitioned into animal-level testing (Aim 3). In more detail, Specific Aim 1 will investigate the hypothesis that novel anti-cancer properties of a subset of SCFA-ManNAc analogs are a consequence of NF-kB inhibition through (at least in part) direct binding to pathway elements such as NFKB1;an auxiliary purpose of this investigation is to discover or design more highly and efficacious analogs for animal testing.
In Specific Aim 2, mass spectrometry and bioinformatics strategies will be used to conduct a glycomics analysis of analog-treated cells;this work will provide a method for pharmacokinetic tracking of analog metabolism in vivo and will also shed mechanistic insights into the role of glycans in metastasis. Finally, Specific Aim 3 will transition this project into animal testing in rodents to determine oral availability, safety, pharmacokinetic properties and organ distribution, and efficacy in metastatic cancer models. Together, these experiments will substantially advance both the mechanistic and translational prospects for SCFA-ManNAc analogs, an emerging class of sugar-based cancer drug candidates.

Public Health Relevance

The ultimate goal of this project is to develop a new class of sugar-based cancer drugs to treat metastatic cancer. Based on the current lack of effective therapeutic agents for virtually all types of highly malignant disease, combined with the hundreds of thousands of new cases of cancer annually, there is clearly an urgent public health need for the drug candidates under development. This project is designed to propel the testing of this emerging class of therapeutics from cell-based assays to rodent models, which will in turn set the stage for translation to clinical testing in humans.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA112314-07
Application #
8243619
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Fu, Yali
Project Start
2004-12-01
Project End
2015-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
7
Fiscal Year
2012
Total Cost
$306,834
Indirect Cost
$119,740
Name
Johns Hopkins University
Department
Biomedical Engineering
Type
Schools of Engineering
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Wang, Xiangchun; Chen, Jing; Li, Qing Kay et al. (2014) Overexpression of ? (1,6) fucosyltransferase associated with aggressive prostate cancer. Glycobiology 24:935-44
Yang, Weiming; Laeyendecker, Oliver; Wendel, Sarah K et al. (2014) Glycoproteomic study reveals altered plasma proteins associated with HIV elite suppressors. Theranostics 4:1153-63
Toghi Eshghi, Shadi; Yang, Shuang; Wang, Xiangchun et al. (2014) Imaging of N-linked glycans from formalin-fixed paraffin-embedded tissue sections using MALDI mass spectrometry. ACS Chem Biol 9:2149-56
Shah, Punit; Yang, Shuang; Sun, Shisheng et al. (2013) Mass spectrometric analysis of sialylated glycans with use of solid-phase labeling of sialic acids. Anal Chem 85:3606-13
Bennun, Sandra V; Yarema, Kevin J; Betenbaugh, Michael J et al. (2013) Integration of the transcriptome and glycome for identification of glycan cell signatures. PLoS Comput Biol 9:e1002813
Almaraz, Ruben T; Aich, Udayanath; Khanna, Hargun S et al. (2012) Metabolic oligosaccharide engineering with N-Acyl functionalized ManNAc analogs: cytotoxicity, metabolic flux, and glycan-display considerations. Biotechnol Bioeng 109:992-1006
Almaraz, Ruben T; Mathew, Mohit P; Tan, Elaine et al. (2012) Metabolic oligosaccharide engineering: implications for selectin-mediated adhesion and leukocyte extravasation. Ann Biomed Eng 40:806-15
Du, Jian; Che, Pao-Lin; Aich, Udayanath et al. (2011) Deciphering glycan linkages involved in Jurkat cell interactions with gold-coated nanofibers via sugar-displayed thiols. Bioorg Med Chem Lett 21:4980-4
Du, Jian; Che, Pao-Lin; Wang, Zhi-Yun et al. (2011) Designing a binding interface for control of cancer cell adhesion via 3D topography and metabolic oligosaccharide engineering. Biomaterials 32:5427-37
Elmouelhi, Noha; Aich, Udayanath; Paruchuri, Venkata D P et al. (2009) Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery. J Med Chem 52:2515-30

Showing the most recent 10 out of 20 publications